Women with Rare Subtype of Ovarian Cancer Could Benefit from Hormone Therapy

Women with Rare Subtype of Ovarian Cancer Could Benefit from Hormone Therapy
Women with low-grade serous carcinoma (LGSC), a rare subtype of epithelial ovarian or peritoneum cancer, are more likely to survive when treated with hormonal therapy after surgery and chemotherapy, new research suggests. In the study, hormonal maintenance therapy following surgery and platinum-based chemotherapy more than doubled the time to disease progression compared with routine observation. Overall survival also increased significantly among the subset of women who achieved a complete response following chemotherapy. The study, "Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum," appeared in the Journal of Clinical Oncology. LGSC, a disease typically diagnosed in women in their 40s or 50s, accounts for 10 percent of serous carcinomas of the ovary/peritoneum. According to prior research by the University of Texas MD Anderson Cancer Center, the disease is more resistant than high-grade serous carcinomas to chemotherapy. "There is a true unmet need for these patients. Roughly 70 percent of women with this disease will experience a recurrence of the cancer at some point," David M. Gershenson, MD, the study's corresponding author, said in a news release. "Our group published research demonstrating that hormonal therapy showed promise in the recurrent setting, with most patients responding or having stable disease. It was a natural progression over time that we began to study this up front, aft
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *